Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Results from the main parts (24 weeks) of 2 concizumab phase 2 trials are presented: explorer4 in hemophilia A (HA) or B (HB) with inhibitors (HAwI/HBwI) and explorer5 in HA. The trials aimed to evaluate the efficacy of daily subcutaneous concizumab prophylaxis (evaluated as annualized bleeding rate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Shapiro, Amy D., Angchaisuksiri, Pantep, Astermark, Jan, Benson, Gary, Castaman, Giancarlo, Chowdary, Pratima, Eichler, Hermann, Jiménez-Yuste, Victor, Kavakli, Kaan, Matsushita, Tadashi, Poulsen, Lone Hvitfeldt, Wheeler, Allison P., Young, Guy, Zupancic-Salek, Silva, Oldenburg, Johannes
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2019
Materias:
Thrombosis and Hemostasis
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895373/
https://ncbi.nlm.nih.gov/pubmed/31444162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001542
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares